Log In
Print this Print this

indatuximab ravtasine (BT-062)

  Manage Alerts
Collapse Summary General Information
Company Biotest AG
DescriptionCD138-targeting mAb with DM4 attached
Molecular Target Syndecan 1 (SDC1) (CD138)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation
PartnerImmunoGen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today